Aerogen

Aerogen is a global leader in acute care aerosol drug delivery, based in Galway, Ireland. Founded in 1997, the company specializes in innovative vibrating mesh nebulizer technology that enhances respiratory treatment for critically ill patients. With over 350 employees and operations in more than 75 countries, Aerogen is recognized for its pioneering role in ICU and hospital-based aerosol drug delivery. The core product, the Aerogen Solo vibrating mesh nebulizer, efficiently converts liquid drugs into aerosols for targeted delivery to the lungs. This technology is particularly beneficial for ventilated patients, including neonates and pre-term infants. Aerogen is also developing advanced devices aimed at reducing the need for invasive intubation. The company is committed to evidence-based innovation, supported by extensive research and clinical partnerships, and has contributed to over 200 clinical publications. Aerogen's products are utilized in over 75 countries, with a significant presence in hospitals, ICUs, and emergency departments. The company has received numerous awards for its excellence in respiratory care and its response to healthcare challenges, highlighting its leadership in medical technology.

• Employees 540
• Founded 1997
• Annual Revenue $129000000
• Total Funding $44076921